Who Paid My Doc
Natella Rakhmanina
Pediatric Infectious Diseases Washington, DC Medical Doctor
NPI 1043397524 CMS profile 506975
111 Michigan Ave Nw, Washington, DC 20010
General payments
$35,751
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$396,843
Through program year 2025, Natella Rakhmanina of Washington, DC is reported in the CMS Open Payments database as having received $35,751 across 27 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $396,843 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $52 | 1 | |
| 2024 | General | $21,714 | 10 | |
| 2023 | General | $7,262 | 13 | |
| 2022 | General | $53 | 1 | |
| 2021 | General | $6,670 | 2 |
Beside peers
- Natella Rakhmanina
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to Natella Rakhmanina were reported at $52. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | Natella Rakhmanina | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $175 | $34–$2,175 | $163 |
| 2020 | $0 | $521 | $34–$6,009 | $114 |
| 2021 | $6,670 | $1,077 | $39–$4,557 | $132 |
| 2022 | $53 | $232 | $53–$6,196 | $149 |
| 2023 | $7,262 | $140 | $52–$4,662 | $160 |
| 2024 | $21,714 | $198 | $52–$3,860 | $164 |
| 2025 | $52 | $126 | $41–$2,094 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
27 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in District of Columbia
Nalini Singh
Pediatric Infectious Diseases · Washington, DC
Sohail Rana
Pediatric Infectious Diseases · Washington, DC
Andrea Hahn
Pediatric Infectious Diseases · Washington, DC
Roberta Debiasi
Pediatric Infectious Diseases · Washington, DC
Merlin Robb
Pediatric Infectious Diseases · Washington DC, DC
Rachel Falik
Pediatric Infectious Diseases · Washington, DC
Related records
Pediatric Infectious Diseases in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.